BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang W, Ling V. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells. J Cell Physiol 2000;184:17-26. [DOI: 10.1002/(sici)1097-4652(200007)184:1<17::aid-jcp2>3.0.co;2-u] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Nicholson R, Menezes AC, Azevedo A, Leckenby A, Davies S, Seedhouse C, Gilkes A, Knapper S, Tonks A, Darley RL. Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux. Front Oncol 2022;12:840046. [DOI: 10.3389/fonc.2022.840046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hennenberg EM, Eyking A, Reis H, Cario E. MDR1A deficiency restrains tumor growth in murine colitis-associated carcinogenesis. PLoS One 2017;12:e0180834. [PMID: 28686677 DOI: 10.1371/journal.pone.0180834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 DeMars KM, Yang C, Hawkins KE, McCrea AO, Siwarski DM, Candelario-Jalil E. Spatiotemporal Changes in P-glycoprotein Levels in Brain and Peripheral Tissues Following Ischemic Stroke in Rats. J Exp Neurosci 2017;11:1179069517701741. [PMID: 28469478 DOI: 10.1177/1179069517701741] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
4 Zhang LH, Yang AJ, Wang M, Liu W, Wang CY, Xie XF, Chen X, Dong JF, Li M. Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. Apoptosis 2016;21:473-88. [PMID: 26767845 DOI: 10.1007/s10495-016-1214-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
5 Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos 2014;42:623-31. [PMID: 24492893 DOI: 10.1124/dmd.113.056176] [Cited by in Crossref: 251] [Cited by in F6Publishing: 259] [Article Influence: 31.4] [Reference Citation Analysis]
6 Lee SD, Osei-Twum JA, Wasan KM. Dose-dependent targeted suppression of P-glycoprotein expression and function in Caco-2 cells. Mol Pharm 2013;10:2323-30. [PMID: 23611024 DOI: 10.1021/mp300668e] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
7 Pinzón-Daza M, Garzón R, Couraud P, Romero Ia, Weksler B, Ghigo D, Bosia A, Riganti C. The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells. Br J Pharmacol 2012;167:1431-47. [PMID: 22788770 DOI: 10.1111/j.1476-5381.2012.02103.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
8 Koshkin V, Krylov SN. Correlation between multi-drug resistance-associated membrane transport in clonal cancer cells and the cell cycle phase. PLoS One 2012;7:e41368. [PMID: 22848474 DOI: 10.1371/journal.pone.0041368] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhang H, Zhang W, Li F. Prognostic significance of MDR-1 P-glycoprotein expression in breast cancer. Journal of Nanjing Medical University 2008;22:148-152. [DOI: 10.1016/s1007-4376(08)60054-4] [Reference Citation Analysis]
10 Randle RA, Raguz S, Higgins CF, Yagüe E. Role of the highly structured 5'-end region of MDR1 mRNA in P-glycoprotein expression. Biochem J 2007;406:445-55. [PMID: 17573715 DOI: 10.1042/BJ20070235] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
11 Souid AK, Gao C, Wang L, Milgrom E, Shen WC. ELM1 is required for multidrug resistance in Saccharomyces cerevisiae. Genetics 2006;173:1919-37. [PMID: 16751665 DOI: 10.1534/genetics.106.057596] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
12 Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4:25. [PMID: 16033649 DOI: 10.1186/1476-4598-4-25] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 5.3] [Reference Citation Analysis]
13 Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 2003;139:35-48. [PMID: 12746221 DOI: 10.1038/sj.bjp.0705227] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 4.9] [Reference Citation Analysis]